There is a particular feeling that belongs to running a small practice. You are simultaneously the clinician, the business owner, the compliance officer, and the person who has to decide whether a $94 denial is worth forty minutes of your evening. Usually it isn't. So it goes in the pile, and the pile becomes a drawer, and the drawer becomes the quiet arithmetic of a practice that works harder every year and doesn't feel any better off.
That feeling is real and it's rational. But the numbers around it are worth knowing, because they don't say what most people assume.
The mistake underneath all the others
Start with the thing nobody wants to hear: most denials are never challenged at all.
Share of denied in-network claims that were appealed in ACA Marketplace plans in 2024, according to KFF's analysis of federal transparency data. Insurers denied 19% of in-network claims that year.
That figure covers consumer appeals in Marketplace plans, not provider appeals in podiatry — no equivalent public dataset exists for the second thing. But it establishes the shape of the problem, and it lines up with what every practice administrator will tell you: denials are far more likely to be absorbed than fought.
What makes that expensive is the other half of the data. In KFF's August 2026 analysis of prior authorization denials, 67% were overturned on appeal in Medicare Advantage, 47% in Medicaid managed care, and 43% in the ACA federally facilitated Marketplace. Appeals are rare. When they happen, a large share succeed.
So the first mistake isn't a technique problem. It's that the appeal never gets written. Everything below is about making the ones you do write count.
Mistake 1: Treating a podiatry denial as a clinical argument
This is the assumption that makes appeals feel unwinnable, and it's usually wrong.
In KFF's review of Marketplace transparency data, only about 2% of in-network denials were based on medical necessity. Roughly 77% fell into administrative and coverage-design categories — excluded services, missing preauthorization or referral, and a large bucket of other administrative reasons.
Read that again with a denial in your hand. The odds are strong that the payer is not disputing your clinical judgment. They're saying a field was wrong, an authorization wasn't on file, or the service sits outside a plan's coverage design. Those are different problems with different fixes, and most of them don't require you to argue medicine at all.
Practically: read the denial code and the remittance advice before you write a word. If the answer is "referral not on file," a beautifully argued clinical narrative is wasted effort — and if the answer genuinely is medical necessity, you now know you're in the 2% and should spend real time on it.
Mistake 2: Resubmitting the same documentation unchanged
Printing the original chart note, attaching the appeal form, and sending it back is the most common approach and the least effective one. If the original documentation had answered the payer's question, the claim would have paid.
An appeal needs to add something the payer didn't have. That might be the conservative treatment history that preceded the orthotic. It might be the systemic diagnosis that establishes why routine foot care was covered. It might just be the authorization number that existed all along and never made it onto the claim.
The appeal should answer the specific reason given, in the order the payer raised it, and say plainly what's enclosed and why.
Mistake 3: Missing the window
Appeal deadlines are short, they vary by payer, and they are enforced without sympathy. Commercial timely-filing windows for appeals commonly run from 60 to 180 days depending on the plan and the appeal level, and Medicare has its own defined levels and timeframes.
For a solo practice, this is where most recoverable revenue is actually lost — not to a weak argument, but to a calendar. A denial that arrives during a busy stretch sits for five weeks, and by the time anyone looks at it the question is moot.
The fix isn't complicated, which is why it's frustrating: a dated log, a recurring block of time, and a rule that denials get triaged the week they arrive even if they aren't worked that week. Confirm the actual deadline for each payer you bill regularly and write it somewhere your staff can see it.
Mistake 4: Overlooking Medicare LCDs and the payer's own policy
Payers publish their coverage rules. Medicare Administrative Contractors publish Local Coverage Determinations; commercial plans publish medical policies. These documents state the criteria a claim is measured against, and they are the closest thing to an answer key that exists.
An appeal that cites the applicable policy by name and addresses its stated criteria in order is a materially different document from one that argues in general terms. It also tells you when not to appeal — if the policy plainly excludes what you billed, the honest answer is that this one isn't winnable, and your evening is better spent on the three that are.
Mistake 5: Treating each denial as a one-off
The single denial is an annoyance. The pattern is the actual money.
If the same code, the same payer, or the same front-desk step is generating denials repeatedly, then every appeal you write is treating a symptom. Practices that track denials by reason code — even in a spreadsheet — usually find that a large share cluster into two or three fixable causes: an eligibility check that isn't happening, a missing authorization step, a diagnosis code that isn't specific enough on the way out the door.
Fixing the upstream cause once is worth more than winning ten appeals, and it doesn't cost you any evenings after the first.
The 2026 skin substitute reimbursement shift for podiatry
If your practice does advanced wound care, this is the most consequential payment change in years, and it isn't an appeals issue — it's a business-model one.
First, what these are and why they land on podiatry
Skin substitutes — also called cellular and tissue-based products, or CTPs — are engineered grafts applied to wounds that won't close on their own. They're used primarily for two indications: diabetic foot ulcers and venous leg ulcers. Both are lower-extremity wounds, which is why podiatry sits at the centre of this category alongside wound care centres and dermatology.
If you manage diabetic ulcers at all, you're in scope. If you refer that work out, you can skip this section — but it's worth knowing what changed, because it affects who's willing to take the referral.
What changed
In the CY 2026 Medicare Physician Fee Schedule final rule, effective January 1, 2026, CMS reclassified most skin substitutes as incident-to supplies rather than separately payable biologicals. Instead of per-product ASP-based pricing, most products are now paid at a single flat national rate — approximately $127.14 per square centimeter after a technical correction issued in November 2025. Only products licensed under Section 351 of the Public Health Service Act with a full BLA continue under the previous ASP methodology.
CMS's stated driver was spending growth: Part B spending on these products rose from roughly $252 million in 2019 to over $10 billion in 2024.
| Element | Before 2026 | From 1 Jan 2026 |
|---|---|---|
| Classification | Separately payable biological | Incident-to supply, bundled with the application procedure |
| Payment basis | Per-product, ASP-based | Flat national rate, approx. $127.14/sq cm |
| Exception | — | Section 351 BLA products remain on ASP methodology |
| Discarded product | Varied | Not separately billable — only the portion applied |
If your procurement assumptions, vendor contracts, or margin expectations were built around the old rates, they need revisiting with your biller. This is a conversation to have with a coding professional who knows your case mix, not something to work out from a blog post.
The December 2025 LCD withdrawal: what podiatrists must track now
There's a second half to this that gets much less attention than the payment rate, and it's the part likeliest to catch a practice out.
The payment change took effect on 1 January 2026 as planned. But on 24 December 2025, CMS withdrew its finalized Local Coverage Determinations for skin substitute grafts in diabetic foot ulcers and venous leg ulcers. So how these products are paid changed on schedule, while which products are covered, and under what clinical criteria, remains unsettled across Medicare Administrative Contractor jurisdictions.
Practical consequence. Any CTP coverage list, episode-of-care limit, or application cap you read that was published before late December 2025 may describe policy that no longer stands. That includes guidance summarising the LCDs that were due to take effect on 1 January.
Check your own MAC's current position directly before relying on anything — including this article. This corner of policy is moving faster than most practices can reasonably track, and it's a reasonable thing to ask your biller to monitor on a set schedule rather than discovering it through a denial.
Podiatry clinical documentation: where the appeal actually comes from
Here is the honest version of the connection between charting and appeals, without the marketing gloss.
An appeal is assembled from the note. If the note was written at eleven at night, five hours and twenty patients after the visit, it is thinner than the encounter was. The specific webspace, the exact measurement, the conservative therapies the patient told you they'd already tried, the reason you chose that particular offloading device — those details existed in the room. Some of them didn't survive the trip to the keyboard.
You cannot appeal with information that was never recorded. That's the whole mechanism, and it's got nothing to do with beating an algorithm.
A line worth holding. There's a genre of advice circulating that frames documentation as a way to get past payer review — write notes that satisfy automated scrubbers, phrase findings so claims clear the filter. Be careful with it.
Documentation records the care you delivered. The moment a phrase enters a chart because it helps a claim rather than because it describes the visit, you've crossed from documentation into something else, and the exposure is yours, not your software vendor's. Write down what happened, in specific terms, because it's true. That it also holds up under review is a consequence, not the goal.
This is where MediAttune fits into podiatry clinical documentation, and the claim is deliberately modest. It listens during the visit and drafts the note from what you said, so the details that existed in the room are still there when you sit down to review, edit and sign. It has no podiatry templates and no clinical logic. It doesn't suggest codes, check modifiers, or shape a note toward any billing outcome. It won't add a finding you didn't state.
Separately, it drafts appeal and prior-authorization letters from case details you type in. That tool has no connection to your EHR and receives no patient data from any integration. It gives you a structured first draft instead of a blank page. It cannot tell you whether a claim will be paid, and neither can anyone else.
How often are denied claims actually appealed?
Rarely. KFF found that consumers appealed fewer than 1% of denied in-network claims in ACA Marketplace plans in 2024. Provider-side appeal behavior isn't captured in that dataset, but the pattern of denials going unchallenged is well documented across payer types.
Are most claim denials about medical necessity?
No. In KFF's analysis of Marketplace transparency data, only about 2% of in-network denials were based on medical necessity, while roughly 77% fell under administrative and coverage-design reasons. Most denials are paperwork problems rather than clinical disagreements.
What changed for skin substitutes in 2026?
Effective 1 January 2026, CMS reclassified most skin substitutes as incident-to supplies rather than separately payable biologicals, paid at a flat national rate of approximately $127.14 per square centimeter. Only Section 351 BLA products continue under ASP-based payment.
Did the 2026 skin substitute coverage rules change too, or just the payment?
Both, but not together. The payment reclassification took effect 1 January 2026. Separately, CMS withdrew its finalized Local Coverage Determinations for skin substitute grafts in diabetic foot ulcers and venous leg ulcers on 24 December 2025, leaving coverage criteria unsettled across MAC jurisdictions. Check your own MAC's current position rather than relying on guidance published before that date.
Does MediAttune write appeal letters?
It drafts them from case details you enter yourself. The letter tool runs separately from the scribe, has no EHR connection, and receives no patient data from any integration. It does not predict or promise any reimbursement outcome.
Sources
KFF, Claims Denials and Appeals in ACA Marketplace Plans in 2024 (denial and appeal rates); KFF analysis of prior authorization denials published August 2026 (overturn rates by program); KFF analysis of Marketplace transparency data on denial reason categories.
CMS, Calendar Year (CY) 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) fact sheet; the November 2025 technical correction to the skin substitute payment rate; and the December 2025 withdrawal of the finalized Local Coverage Determinations for skin substitute grafts in diabetic foot ulcers and venous leg ulcers.
Appeal deadlines, coverage policies, and coding requirements vary by payer and change frequently. This article is general information for practice owners, not billing, coding, or legal advice. Confirm current requirements with your biller or a certified coding professional before acting on anything here.